Despite the slow market thaw in recent years, 18 biotech companies have priced out IPOs through September 2024, but going ...

Relay Therapeutics faces challenges with limited clinical data and high expenses but shows promise with their 4D drug design ...

After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months as a series of companies announced plans to go public. Market watchers had expected a busy first ...

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and ...

It added that while the number of biotech deals in 2023 was comparatively low at just 11, those that moved forward were larger, with the average IPO size jumping to $253M from a previous high of $ ...

After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model. A commonly held perception in the biotech ...

Legend Biotech is spinning out from parent firm GenScript Biotech to pursue treatments in CAR T cell therapies for multiple myeloma. Legend Biotech is spinning out from parent firm GenScript ...

Going public with a valuation higher than $300 million may now be necessary to attract interest from institutional investors. A few times over the past two decades, a confluence of forces has ...

Windlas Biotech IPO opens on August 4 and closes on August 6. Demat account, trading application and UPI ID are mandatory if you are applying for an initial public offering (IPO). Windlas Biotech ...

Concord Biotech is expected to announce its share allotment status today, August 11. The shares of Concord Biotech were subscribed almost 25 times. The shares are expected to be listed on the ...